Theoretical Basis of Pathogenic Substance Removal During Plasmapheresis

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 5, 2011, Pages 421-430

  Hanafusa, Norio ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Compartment; Distribution volume; Molecular weight; Plasmapheresis; Production rate

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 13; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G;

ANTIGEN ANTIBODY REACTION; BLEEDING; BLEEDING TIME; BLOOD LEVEL; BODY FLUID COMPARTMENT; CENTRIFUGATION; DIFFUSION; DISEASE SEVERITY; DISTRIBUTION VOLUME; ELECTRICITY; EXTRACELLULAR FLUID; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INFECTION COMPLICATION; MEMBRANE FILTER; MOLECULAR WEIGHT; ONCOTIC PRESSURE; PLASMA VOLUME; PLASMAPHERESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RELATIVE DENSITY; REVIEW;

HEMORRHAGE; HUMANS; INFECTION; MEMBRANES, ARTIFICIAL; MOLECULAR WEIGHT; PLASMA VOLUME; PLASMAPHERESIS;

EID: 80955180928     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00930.x     Document Type: Review

References (26)

1. Hirata N, Shizume Y, Shirokaze J, Suemitsu J, Yoshida H, Yamawaki N. Plasma separator plasmaflo OP. Ther Apher Dial 2003;7:64-8.
2. Nakaji S, Yamamoto T. Membranes for therapeutic apheresis. Ther Apher 2002;6:267-70.
3. Maher JF. Principles of dialysis and dialysis of drugs. Am J Med 1977;62:475-81.
4. Hidaka T, Suzuki K, Matsuki Y etal. Evaluation of adsorption selectivity dextran sulfate bound cellulose beads for the removal of anti-DNA antibodies. Ther Apher 1999;3:75-80.
5. Kaplan AA. Towards a rational prescription of plasma exchange: the kinetics of immunoglobulin removal. Semin Dial 1992;5:227-9.
6. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008;52:1180-96.
7. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003;138:105-8.
8. Jayne DR, Gaskin G, Rasmussen N etal. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.
9. Ziedins KB, Orfeo T, Jenny NS, Everse SJ, Mann KG. Blood coagulation and fibrinolysis. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, eds. Wintrobe's Clinical Hematology, 12th edn. Philadelphia, PA: Wolters Kluwer Health, Lippincott Wiliams & Wilkins, 2009; 528-619.
10. Fujiwara K, Kaneko S, Kakumu S etal. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 2007;37:701-10.
11. Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993;7:229- 42.
12. Gerlach R, Raabe A, Zimmermann M, Siegemund A, Seifert V. Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. Surg Neurol 2000;54:260-4 discussion 264-265.
13. Hanafusa N, Kondo Y, Suzuki M, Nakao A, Noiri E, Fujita T. Double filtration plasmapheresis can decrease factor XIII Activity. Ther Apher Dial 2007;11:165-70.
14. Hanafusa N, Satonaka H, Doi K, Noiri E, Fujita T. Virus removal and eradication by modified double filtration plasmapheresis decreases factor XIII levels. Ther Apher Dial 2010;14:287-91.
15. Seishima M, Shibuya Y, Kato G, Aoki T. Decreased factor XIII activity in a patient with subcutaneous bleeding after double filtration plasmapheresis. Ther Apher Dial 2009;13:229-31.
16. Hanafusa N, Aozasa N, Fujita T. A patient whose factor XIII level was decreased by double filtrate plasmapheresis and successfully recovered by infusion of factor XIII concentrate. Ther Apher Dial 2010;14:432-3.
17. Pohl MA, Lan SP, Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 1991;114:924-9.
18. Mineshima M, Agishi T, Hasuo Y etal. Optimum albumin concentration of supplementation fluid for double filtration plasmapheresis. Artif Organs 1992;16:510-13.
19. Silberstein LE, Naryshkin S, Haddad JJ, Strauss JF, 3rd. Calcium homeostasis during therapeutic plasma exchange. Transfusion 1986;26:151-5.
20. Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr 1997;109:123-7.
21. Kramer L, Bauer E, Joukhadar C etal. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003;31:2450-5.
22. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994;23:817-27.
23. Kankirawatana S, Huang ST, Marques MB. Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange. J Clin Apher 2007;22:265-9.
24. Abe T, Kobata H, Hanba Y etal. Study of plasma exchange for liver failure: beneficial and harmful effects. Ther Apher Dial 2004;8:180-4.
25. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1727 procedures. J Clin Apher 2007;22:270-6.
26. Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 2005;9:391-5.